Drug Landscape ›
Uro-Vaxom ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 52
Most-reported reactions
Urinary Tract Infection — 10 reports (19.23%) Headache — 7 reports (13.46%) Dyspnoea — 5 reports (9.62%) Pain — 5 reports (9.62%) Vision Blurred — 5 reports (9.62%) Chest Discomfort — 4 reports (7.69%) Confusional State — 4 reports (7.69%) Dry Eye — 4 reports (7.69%) Eye Irritation — 4 reports (7.69%) Fatigue — 4 reports (7.69%)
Source database →
Uro-Vaxom in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Uro-Vaxom approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Uro-Vaxom in United States?
Swiss Paraplegic Research, Nottwil is the originator. The local marketing authorisation holder may differ — check the official source linked above.